OXFORD, England, November 19, 2013 /PRNewswire/ -- Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of two new open access journals in its cardiology journals series: International Journal of Cardiology-Heart & VesselsandInternational Journal of Cardiology-Metabolic & Endocrine. Heart disease is the leading cause of deaths worldwide, with nearly 600,000 deaths in the US alone in 2011, according to the United States Centers for Disease Control and Prevention. Both new journals will publish essential research in the field of cardiology open access, enabling the latest research to be freely available worldwide. "With 12.9 million deaths from ischaemic heart disease and stroke in 2010, representing a quarter of total deaths*, considerable research is taking place to diagnose and treat this condition, and others such as hypertension and thrombosis," said Prof. Michael Henein, Umeå Heart Centre, Sweden, Editor-in-Chief of the International Journal of Cardiology (IJC): Heart & Vessels. "The new journal will be the natural home for this field of research, publishing articles and reviews on structural and functional cardiovascular pathology, with an emphasis on cardiovascular imaging, disease pathophysiology and management," Prof. Henein continued. "I am honored to be appointed Editor-in-Chief of this journal and would like to invite researchers in these fields to submit their best papers for consideration." Prof. Giuseppe Rosano, of the IRCCS San Raffaele Pisana, Italy, will serve as Editor-in-Chief of International Journal of Cardiology (IJC):Metabolic & Endocrine which will be devoted to cardiovascular medicine in general and to the interplay between the cardiovascular system metabolism and hormones in particular. The journal will also publish articles reporting the effect of clinical trials and therapeutic interventions affecting the metabolic and/or hormonal influences on the cardiovascular system. "The journal will have a specific focus on the cardiovascular effects of diseases with mixed metabolic and endocrine pathophysiology, such as arterial hypertension and diabetes mellitus. It will serve the interests of both practising clinicians and researchers," specified Prof. Rosano.